Fig. 4

LLC cells viability at 24 (a), 48 (b), 72 h (c) of treatment with the free Ber or C₆₀–Ber nanocomplexes in a Ber-equivalent concentration and at treatment with the free C₆₀ in concentrations equivalent to that in nanocomplexes (d); *p < 0.05 compared to control; #p < 0.05 compared to free Ber